Projects

Projects per year 2004 2006 2009 2011 2013 2019 2028

• 8 Active
• 22 Finished

Projects per year

Search results

• Active

  ANI389: Development of a B7-H3 nanoCAR-T cell therapy for recurrent glioblastoma (GlioCAR)

  Neyns, B., Geeraerts, X., Tuyaerts, S., Breckpot, K., Duerinck, J. & Smolders, I.

  1/10/24 → 30/09/28

  Project: Fundamental

• ANI352: MOTUNE-T therapy: Metabolically Optimized TUNEd T cells as treatment for recurrent glioblastoma

  Neyns, B. & Geeraerts, X.

  1/10/23 → 30/09/27

  Project: Fundamental

  • Glioblastoma 100%
  • T-Lymphocytes 48%
  • Ipilimumab 31%
  • Nivolumab 30%
  • Therapeutics 22%

• FWOTM1132: Health-related quality of life, psychosocial outcome and neurocognitive function in metastatic cancer survivors treated with immunotherapy, followed by integrative neurocognitive remediation therapy

  Neyns, B., Rogiers, A. & Vanlaer, N.

  1/11/22 → 31/10/26

  Project: Fundamental

  • Cancer Survivors 100%
  • Immunotherapy 70%
  • Quality of Life 44%
  • Therapeutics 14%
  • Cognitive Behavioral Therapy 11%

• FWOEOS18: Exploring the mechanisms of RESponse and RESistance to novel Cancer immunotherapies in tumors Unresponsive to Earlier immune checkpoint inhibition

  Neyns, B., Breckpot, K. & Tuyaerts, S.

  1/01/22 → 31/12/25

  Project: Fundamental

  • tumors 100%
  • cancer 97%
  • Neoplasms 33%
  • Immunotherapy 20%
  • Adoptive Immunotherapy 15%

• ANI214: Clinical PET/CT imaging of protumorigenic macrophages using anti-MMR-68-Ga-Nanobody: a promising biomarker tool to predict treatmnet response.

  Lahoutte, T., Keyaerts, M., Neyns, B. & Waelput, W.

  1/01/19 → 31/12/24

  Project: Fundamental

  • Single-Domain Antibodies 100%
  • macrophages 97%
  • biomarkers 89%
  • arts 82%
  • 1,4,7-triazacyclononane-N,N',N''-triacetic acid 58%

• ANI40: A stratified phase II study of the aniti-EGFR monoclonal antibody cetuximab (Erbitux TM) for the treatment of recurrent glioblastoma multiforme.

  Neyns, B. & De Grève, J.

  17/01/06 → …

  Project: Fundamental

  • Cetuximab 100%
  • Glioblastoma 78%
  • Monoclonal Antibodies 58%

• ANI41: Improvement and integration of specific melanoma antigen DC-based vaccination with chemo-and cytokine therapy for the treatment of advanced melanoma patient.

  De Grève, J. & Neyns, B.

  17/01/06 → …

  Project: Fundamental

  • Melanoma-Specific Antigens 100%
  • Melanoma 59%
  • Vaccination 57%
  • Cytokines 44%
  • Therapeutics 11%

• ANI27: Therapeutic vaccination of cancer patients with defined tumor antigens recognized by T lymphocytes.

  De Grève, J. & Neyns, B.

  16/01/04 → …

  Project: Fundamental